Multi-resistant Gram-negative Bacteria Cause Infection
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
CT
Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang
1 program1
TQD3524Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
Chia Tai TianQing Pharmaceutical GroupTQD3524
Clinical Trials (1)
To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects
Start: Jul 2024Est. completion: Dec 2025
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space